Kornimate/medical-research-clean huggingface dataset:
breathing and core stability exercise effects on lumbopelvic pain

Conditions: Breathing Sound; Low Back Pain; Post-operative Pain; Pelvic Pain

Summary: lumbopelvic pain refers to self-reported pain in areas of lower region, anterior and posterior pelvic tilt or combination of these. physical therapy interventions used are breathing exercises with and without core stability exercises. tool used were pain pressure algometer and oswestry disability index.

lumbopelvic pain is self-reported pain. it is common complaint for women after labour, and it is found that 25% of newly delivered women experienced low back and pelvic pain. different interventions have been used to reduce the lumbopelvic pain in general including exercises, drugs, therapies and massage. an increasingly common approach used within physical therapy management are breathing exercises and core stabilization exercises. this study will used to compare the effects of breathing exercises with and without core stability exercise. pre-assessment will be done using oswestry disability index as subjective measurement and pain pressure algometer as objective measure.

Eligibility criteria:
inclusion criteria: * women had parity (2-4) times * body mass index that did not exceed 30 kg/m * lumbopelvic pain at least three months until one year postpartum exclusion criteria: * they were pregnant * had systemic inflammatory diseases * prolapsed disc * neuromuscular disorder

Keywords: breathing exercises low back pain post-partum pain lumbopelvic pain
implementation and evaluation of a social journey accompanied in breast cancer diagnosis (epars sein)

Conditions: Breast Cancer

Summary: evaluate and compare the return to work rate at 12 months

evaluate and compare the return to work rate at 12 months (from j1c1 \[first day of the first adjuvant chemotherapy regimen\]) between the "intervention" group (which has accompanied the career) and the standard group course

Eligibility criteria:
inclusion criteria: * patient major\> 18 * have a diagnosis of localized breast cancer requiring surgery immediately adjuvant therapy sequence including chemotherapy and radiotherapy * being more than 3 years of retirement at diagnosis * have a work contract valid at the time of diagnosis (before surgery) * do not practice a profession * be in possession of his rights (excluding guardianship, curatorship) * raise the general social security scheme and have rights to cash benefits in the languedoc-roussillon region exclusion criteria: * patient minor * patient diagnosed with metastatic breast cancer * patients refusing to sign the consent * patients do not have sufficient understanding of the french language * patients for whom it is impossible to give clear information
atrial fibrillation data linkage non-interventional study

Conditions: Atrial Fibrillation

Summary: the purpose of this study is to understand temporal changes in clinical features and functions, and the relationship with outcomes of atrial fibrillation (af). af is a problem with speed or pattern that the heart beats. it is the most common type of arrythmia. the study will use data linkage of a single center patient data and national claims database in korea. this study does not include an actual patient enrollment process.


Eligibility criteria:
inclusion criteria: * patients had incident af diagnosis (international classification of diseases 10th revision \[icd-10\]; i48) in an inpatient or outpatient setting at snuh between 1 jan 2010 and 31 dec 2020 * patients aged 18 years or older on the index date exclusion criteria: * medical claims indicating a diagnosis code indicative of rheumatic mitral valvular heart disease, mitral valve stenosis, or prosthetic heart valve during 12 months period prior to first af diagnosis
a single arm, open-label first in human study for assessing the safety and performance of the epifinder in subjects with clinical indication for lumbar epidural steroids injection (esi)

Conditions: Chronic Pain

Summary: the epifinder device, which is the investigational device in this study, is intended for use in epidural procedures, between a luer syringe and an epidural needle, to give the treating physician a clear indication that the needle tip has entered the epidural space. the objective of this first in human study is to evaluate the safety and performance of using the epifinder to identify the epidural space in subjects with a clinical indication to receive a lumbar epidural steroid injections.


Eligibility criteria:
inclusion criteria: * subject is 18 years or older * subject with clinical indication for lumbar esi based on subject's clinical problem (e.g. ddd hernia disc, spinal stenosis) * subject understands the study requirements and the treatment procedures and provides written informed consent before any study-specific tests or procedures are performed exclusion criteria: * subject with marked spinal deformities * previous back surgery * contraindication for epidural injections (e.g. continuous use of anticoagulants, infection, allergic reactions to the injected substances) * subject has known hypersensitivity to contrast media that cannot be pre-medicated * subject with severe obesity (body mass index \>35 kg/m2) * subject observed seizure within 7 days prior to study enrollment * subject presenting for emergency * subject has a skin condition (i.e., hemangioma, scleroderma, psoriasis, rash, open wound or tattoo) in their lumbar region * subject is pregnant (to be determined by urine pregnancy test) * subject who is currently participating or has participated in an investigational study, within the past 30 days
a clinical trial of a vitamin/nutriceutical formulation for alzheimer's disease

Conditions: Alzheimer's Disease; Mild Cognitive Impairment

Summary: based on prior published pilot studies, the investigators have initiated a larger, multi-site placebo-controlled clinical trial with alzheimer's disease (ad) patients and individuals diagnosed with mild cognitive impairment (mci), with the hopes of (1) confirming (or denying) the above promising clinical findings, and (2) determining whether or not our formulation can delay mci "conversion" to ad.

preclinical studies with mouse models of of age-related neurodegeneration led us to develop a nutriceutical formulation ("nf") consisting of 6 over-the-counter vitamins and nutriceuticals, that buffers multiple facets of alzheimer's disease (ad), including (1) reducing presenilin expression, gamma-secretase activity, abeta generation and tau phosphorylation, (2) buffering homocysteine and abeta-induced oxidative damage, (3) reducing aggression, (4) increasing acetylcholine production and improving/maintaining cognitive performance. a 1-year, open-label trial with nf with mild to moderate ad patients demonstrate improvement in cognitive performance (dementia rating scale, clock-drawing) within 3-6 months. caregivers reported maintenance of daily performance and improved mood (adcs-activities of daily living and neuropsychiatric inventory). a placebo-controlled study with moderate to late-stage ad indicates delayed cognitive decline and maintenance of daily activities. no adverse events were reported. a multi-site trial with \>90 individuals aged 45-73 without dementia indicated that nf statistically improved executive function (trails b-a) vs. placebo within 3 months, which increased further at 6 months. the placebo group demonstrated identical improvement in a 3-month open-label extension. following nf withdrawal, participants returned to baseline; statistically-significant improvement was restored once nf was individuals resumed. we have initiated a larger, multi-site placebo-controlled clinical trial with ad patients and individuals diagnosed with mild cognitive impairment (mci), with the hopes of (1) confirming (or denying) the above promising clinical findings, and (2) determining whether or not our formulation can delay mci "conversion" to ad.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of alzheimer's disease or mild cognitive impairment * must be able to swallow pills exclusion criteria: * known or suspected bipolar disorder

Keywords: dietary supplement cognition mood alzheimer's disease memory loss
management of acute heart failure: contribution of ultrasound daily "in bed patient" adjustment on therapy with impact measure on re hospital rate during 30 days

Conditions: Heart Failure

Summary: our hypothesis: a daily bedside echocardiographic assessment, protocolized, simple and reproducible estimation of filling pressures with an evaluation of mitral inflow and the inferior vena cava, allow a more reliable estimate of the true blood volume of the patient and thus lead to a therapeutic adjustment more suitable. this therapeutic adjustment closer to patient's needs would impact fewer readmissions at 30 days and mortality, less alteration of biological parameters myocardial, kidney and liver.


Eligibility criteria:
inclusion criteria: the patient or his representative must be given free and informed consent and signed consent. * the patient must be affiliated or beneficiary of a health insurance plan. * the patient is available for a follow-up 6 months. * the patient is of age or older (\>) 18. * patients hospitalized for acute heart failure who received at least 40mg of furosemide iv. * patient with impaired lvef \<50%. * patient with nt-probnp values\> 1200pg / ml. exclusion criteria: * the subject takes part in another study. * the subject is exclusion period determined by a previous study. * the subject is under judicial protection. * the subject or his representative refuses to sign the consent. * it is not possible to give the subject or his representative informed information. non-inclusion criteria for those diseases or conditions associated (s) interfere (s): * the patient is pregnant or is breastfeeding. * the patient is already included in a surveillance program (prado, osicat). * patient with a mechanical or biological mitral prosthesis. * history of mitral stenosis. * severe valvular surgery with maturity in months (\<30 days). * chronic renal impairment on dialysis. * high grade av block (avb and bav3 2/1). * hypertrophic cardiomyopathy. * cardiogenic shock. * contraindications to furosemide.

Keywords: bedside echography
a study of efavirenz in hiv-infected patients who have never taken anti-hiv drugs

Conditions: HIV Infections

Summary: the purpose of this study is to see if it is safe and effective to give efavirenz plus stavudine plus lamivudine to patients who have never taken anti-hiv drugs.

patients will be given combination treatment with efavirenz, stavudine, and lamivudine.

Eligibility criteria:
inclusion criteria patients must have: * documented diagnosis of hiv infection with plasma hiv-rna greater than or equal to 10,000 copies/ml. * life expectancy of at least 12 months. exclusion criteria co-existing condition: patients with the following symptoms or conditions are excluded: * current bilateral peripheral neuropathy greater than or equal to grade 2. * proven or suspected acute hepatitis due to any cause. * recurrent episodes of moderate to severe diarrhea, or vomiting lasting for more than 4 days within 3 months prior to dosing. * hypersensitivity to any component of the formulation of efavirenz, stavudine, or lamivudine. * any clinically significant laboratory findings obtained during the screening evaluation (see laboratory values). * any clinically significant disease (other than hiv infection) or clinically significant findings found during the screening of medical history or physical examination. * any malignancy that requires systemic therapy. * any active aids-defining opportunistic infection or disease. concurrent medication: excluded: astemizole, cisapride, clarithromycin, ketoconazole, itraconazole, midazolam, rifabutin, rifampin, terfenadine, thalidomide, triazolam, vincristine, zalcitabine or any medications contraindicated for concomitant use with stavudine or lamivudine as described in the current information package insert. patients with the following prior conditions are excluded: * history of acute or chronic pancreatitis. * a life expectancy of less than 12 months. * difficulty swallowing capsules/tablets. * inability to communicate effectively with study personnel. prior medication: excluded: * any other experimental drug within 30 days of introducing study treatment. * vaccination within 3 weeks of screening visit. * any prior antiretroviral therapy. * interferon started within 30 days of initiating study treatment. risk behavior: excluded: current alcohol or illicit drug use which interferes with patient's ability to follow study regimen.

Keywords: drug therapy, combination stavudine lamivudine reverse transcriptase inhibitors efavirenz
atelectasis by lung ultrasonography in cesarean sections

Conditions: Atelectasis; Cesarean Section

Summary: in this study aimed to demonstrate that atelectasis developing in the perioperative period of patients undergoing elective cesarean surgery with spinal or general anesthesia methods using lung ultrasound. after preoperative lung ultrasounds of patients is done, the cesarean operation will be completed with spinal or general anesthesia. in the postoperative period, control lung ultrasounds will be performed and the ultrasound results will be compared in terms of atelectasis in both groups.


Eligibility criteria:
inclusion criteria: * between 18-40 years * 37-40 weeks pregnant * asa ii because of pregnancy exclusion criteria: * emergency cesarean sections * who refuse to participate in the study * with chronic disease * smoker * with chest deformity
topical cyclosporine for vernal keratoconjunctivitis (vkc) in rwanda

Conditions: Vernal Keratoconjunctivitis

Summary: vernal keratoconjunctivitis (vkc) is a bilateral, chronic, external ocular inflammatory disease of unknown cause. it is a fairly common disease in hot, dry environments, representing as much as 3% of severe ophthalmic diseases and up to 33% of all eye pathology seen among young patients in eye clinics in central africa. symptoms and signs can persist for years with an important visual morbidity and social impact. corneal changes (e.g. corneal ulcers) can be sight threatening, occurring in up to 10% of vkc children. topical steroid therapy remains the current standard treatment, but in developing countries its use often is chronic and not medically supervised, potentially leading to bacterial infections, steroid-induced glaucoma and cataract. chromoglycate drops have less side effects but lack the power to control a flare-up. topical cyclosporine has the potential to offer an efficient but safer alternative to steroid drops in the management of vkc in an african setting. its safety and efficiency in the management of vernal keratoconjunctivitis have been described in several uncontrolled studies and double-blind, placebo-controlled trials, but those studies were relatively small and involved populations outside africa with predominantly palpebral and mixed forms of vkc. controversy still remains on the efficiency of cyclosporine in severe forms of allergic conjunctivitis like vkc. we therefore undertake a larger prospective randomized double-masked, standard treatment controlled clinical trial in central africa to compare the short-term efficiency of cyclosporine a (csa) 2% eye drops, solved in olive oil vehicle, with that of steroid drops in predominantly limbal forms of vkc. during 4 weeks the participants will be randomised to either cyclosporine or dexamethasone as attack treatment for vkc. the 4 weeks thereafter all participants will receive chromoglycate drops as maintenance treatment. additional objectives are to document any difference in rebound phenomenon while on chromoglycate during the maintenance phase between the 2 treatment groups and to evaluate safety and tolerance of the test medication.


Eligibility criteria:
inclusion criteria: - at least 5 years of age exclusion criteria: * being pregnant * suffering from any other infectious or inflammatory ocular pathology * using topical/ systemic corticosteroids, antihistamines, non-steroidal anti-inflammatory drugs or immunosuppressives 2 weeks prior to the trial * been treated with steroid injection 6 months prior to the study
emotional and social impact on the relatives of hospitalized children for severe trauma

Conditions: Severe Trauma

Summary: this research aims to study the occurrence of post-traumatic stress, anxiety or depression in the parents of a child who has been hospitalized in intensive care unit following a severe trauma.

with nearly 25% of trauma deaths, trauma is one of the leading causes of death in the world for children aged 5 to 14 years. in children under 4, it is responsible for 6% of deaths. severe trauma is defined by an abbreviated injury scale \> 3 score in at least one anatomical region. in case of multiple traumas, the injury severity score is used to define severe polytrauma if it is \> 15. cranial trauma is the most common lesion found in polytraumatized children and is present in 80% of cases. serious head trauma is defined as the existence of a cranial trauma in a patient whose glasgow score is less than or equal to 8. severe trauma is a source of high mortality and severe disability in surviving children. due to the context of sudden onset, a prolonged length of hospitalization in intensive care, as well as the occurrence of often severe sequelae, the severe trauma causes a real upheaval for the child's relatives. in adults, the occurrence of post-traumatic stress, anxiety and depression is relatively well described in patients and relatives of patients who have been hospitalized in intensive care unit. however, there is currently no pediatric study focusing on this subject, apart from neonatology where the traumatological context remains exceptional. this research aims to study the occurrence of post-traumatic stress, anxiety or depression in the parents of a child who has been hospitalized in intensive care unit following a severe trauma.

Eligibility criteria:
inclusion criteria: * holder of the parental authority of a patient under 18 who has been hospitalized in the surgical intensive care unit of necker university hospital for severe trauma (abbreviated injury scale greater than or equal to 3 in one of the anatomical regions) at the admission in the service and regardless of the ending of hospitalization. * holder of parental authority over 18 years. * holder of parental authority speaking french. exclusion criteria: * holder of parental authority refusing to participate in the study, after submission of the information document. * holder of parental authority unable to answer the questionnaire.

Keywords: severe trauma post-traumatic stress anxiety depression intensive care
fmri cholinergic mechanisms in schizophrenia

Conditions: Schizophrenia

Summary: this study aims to determine how clozapine treatment improves neuronal measures of sensory gating in subjects with schizophrenia.

this study will use functional magnetic resonance imaging (fmri) to study patients treated with risperidone, a commonly used neuroleptic that does not improves sensory gating, to those treated with clozapine to determine which brain areas are involved in clozapine's normalization of sensory gating in schizophrenia.

Eligibility criteria:
inclusion criteria: * diagnosis of schizophrenia * age 18-60 yrs exclusion criteria: * claustrophobia * weight \> 250 lbs * metal in body other than dental fillings
advate/ adynovi hemophilia a outcome database (ahead)

Conditions: Hemophilia A

Summary: the purpose of the study is to document the natural history of hemophilia a disease and long-term outcomes in terms of effectiveness, safety and quality of life in participants receiving antihemophilic factor (recombinant) - plasma/albumin free method (rahf-pfm) or antihemophilic factor (recombinant) - pegylated (rahf-peg) in routine clinical practice


Eligibility criteria:
inclusion criteria: * participant has hemophilia a {fviii lesser than or equal to (\<=)5%} * participant is prescribed antihemophilic factor (recombinant) - plasma/albumin free method (rahf-pfm) or antihemophilic factor (recombinant) - pegylated (rahf-peg) by the treating physician * participant or participant's legally authorized representative provides informed consent exclusion criteria: * participant has known hypersensitivity to the active substance or any of the excipients * participant has known allergic reaction to mouse or hamster proteins * participant has participated in another clinical study involving an investigational product (ip) or device within 30 days prior to study enrollment or is scheduled to participate in another clinical study involving another fviii concentrate or device during the course of this study
effect of topical prostaglandin f2α analogs,fractional co2 laser, excimer laser or their combination in treatment of vitiligo

Conditions: Vitiligo; Excimer Laser; Fractional CO2 Laser

Summary: vitiligo is a chronic disease with an unpredictable clinical course, characterized by the appearance of white macules and patches on the skin and mucous membranes due to the disappearance of melanocytes in the affected area. it affects approximately 0.5% - 2% of the population worldwide and may occur at any age. vitiligo is caused by a dynamic interplay between genetic and environmental risks that initiates an autoimmune attack on melanocytes in the skin.

the treatment of vitiligo has been a challenge for dermatologists. recent reports have highlighted darkening of iris, and eyelashes and periocular hyperpigmentation induced by prostaglandin f2α analogues used for the treatment of glaucoma (as travoprost). extrapolating these findings in the treatment of vitiligo. the beneficial effect of fractional co2 laser on vitiligo is postulated to come from the release of cytokines and growth factors that act as mitogens for melanogenesis . the preceding laser also alters the skin barrier, which results in increased penetration of topical drugs and ultraviolet (uv) radiation. 308 nm excimer laser is a monochromatic, target type treatment and allows the delivery of higher fluences to the lesions and avoids damage to the surrounding normal skin resulting in a faster and more effective pigmentation with minimal side effects.

Eligibility criteria:
inclusion criteria: 1. patients older than 12 years. 2. patients with generalized non-segmental vitiligo. 3. no previous treatment for vitiligo in the last 1 month. 4. patients who were unresponsive to medical treatment or photo therapy for at least 3 months. exclusion criteria: 1. patients with sensitivity to travoprost. 2. patients with photosensitivity. 3. patients with history or active skin cancer. 4. no other dermatological or systemic diseases. 5. active infections . 6. pregnant or lactating females.